Testosterone and cardiovascular risk in men

Frontiers of Hormone Research

Volumn 43, Issue , 2014, Pages 1-20

  Kelly, Daniel M ^a   Jones, T Hugh ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b BARNSLEY DISTRICT GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE; VASODILATOR AGENT;

ANDROGEN DEFICIENCY; ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; ANGINA PECTORIS; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HUMAN; HYPERTENSION; INFLAMMATION; ISCHEMIC HEART DISEASE; MALE; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; ADULT; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DEFICIENCY; DRUG EFFECTS; ENDOTHELIUM; HORMONE SUBSTITUTION; HYPOGONADISM; MIDDLE AGED; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; RISK FACTOR; VASODILATATION;

ADULT; ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM; HEART FAILURE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; RISK FACTORS; TESTOSTERONE; VASODILATION;

EID: 84920388313     PISSN: 03013073     EISSN: 16623762     Source Type: Book Series    
DOI: 10.1159/000360553     Document Type: Article

References (26)

1. Jones TH: Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol Metab 2010; 21: 496-503 .
2. Ohlsson C, Barrett-Connor E, Bhasin S, Orwoll E, Labrie F, Karlsson MK, Ljunggren O, Vandenput L, Mellström D, Tivesten A: High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) Study in Sweden. J Am Coll Cardiol 2011; 58: 1674-1681.
3. Hyde Z, Norman PE, Flicker L, Hankey GJ, Almeida OP, McCaul KA, Chubb SA, Yeap BB: Low free testosterone predicts mortality from cardiovascular disease but not other causes: the Health in Men Study. J Clin Endocrinol Metab 2012; 97: 179-189.
4. Jones RD, Nettleship JE, Kapoor D, Jones HT, Channer KS: Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiovasc Drugs 2005; 5: 141-154.
5. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA: Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96: 3007-3019.
6. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N; American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association: Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association endorsed by the American Society for Radiation Oncology. Circulation 2010; 121: 833-840.
7. Grossmann M: Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab 2011; 96: 2341-2353.
8. Kelly DM, Jones TH: Testosterone: a metabolic hormone in health and disease. J Endocrinol 2013; 217: R25-R45.
9. Rao PM, Kelly DM, Jones TH: Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nat Rev Endocrinol 2013; 9: 479-493.
10. Wang C, Jackson G, Jones TH, Matsumoto AM, Nehra A, Perelman MA, Swerdloff RS, Traish A, Zitzmann M, Cunningham G: Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 2011; 34: 1669-1675.
11. Saad F, Haider A, Doros G, Traish A: Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring) 2013; 21: 1975-1981.
12. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A: Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a metaanalysis. Clin Endocrinol (Oxf) 2005; 63: 280-293.
13. Jones TH, Saad F: The effect of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis 2009; 207: 318-327.
14. Keating NL, O'Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-4456.
15. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH: Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 2013; 169: 725-733.
16. Kelly DM, Jones TH: Testosterone: a vascular hormone in health and disease. J Endocrinol 2013; 217: R47-R71.
17. Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, Bakal JA, Armstrong PW, Ezekowitz JA: Testosterone supplementation in heart failure: a meta-analysis. Circ Heart Fail 2012; 5: 315-321.
18. Malkin CJ, Channer KS, Jones TH: Testosterone and heart failure. Curr Opin Endocrinol Diabetes Obes 2010; 17: 262-268.
19. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, Uraga MV, Erwin PJ, Montori VM: Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007; 82: 29-39.
20. Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, Agrwal N, Elamin MB, Gallegos-Orozco JF, Wang AT, Erwin PJ, Bhasin S, Montori VM: Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95: 2560-2575.
21. Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, Forti G, Mannucci E, Maggi M: Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 2011; 165: 687-701.
22. Carson CC 3rd, Rosano G: Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data. J Sex Med 2012; 9: 54-67.
23. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, Eder R, Tennstedt S, Ulloor J, Zhang A, Choong K, Lakshman KM, Mazer NA, Miciek R, Krasnoff J, Elmi A, Knapp PE, Brooks B, Appleman E, Aggarwal S, Bhasin G, Hede-Brierley L, Bhatia A, Collins L, LeBrasseur N, Fiore LD, Bhasin S: Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109-122.
24. Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, Oldham JA, Wu FC: Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010; 95: 639-650.
25. Vigen R, O'Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, Barqawi A, Woning G, Wierman ME, Plomondon ME, Rumsfeld JS, Ho PM: Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013; 310: 1829-1836.
26. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM: Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012; 97: 2050-2058.